GlassScriptPhysician profile
Gary Alan Cohen
NPI 1346424462
$10,148.72
in general payments reported to CMS, 2019-2025
28 companies · $1,073 in 2025
The $1,073 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $1,407 · 2021: $1,685 · 2022: $1,598 · 2023: $1,756 · 2024: $1,451 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,279.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,799.75 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,735.46 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $1,501.91 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $858.93 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $662.69 | 2019-2025 | |
| Kaleo, INC. | $614.25 | 2019-2023 | Auvi-Q |
| Pfizer INC. | $612.80 | 2019-2025 | |
| Optinose US, INC. | $347.37 | 2019-2025 | |
| Genentech USA, INC. | $253.33 | 2021-2024 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.67 | 2020-2022 | |
| Biocryst US Sales Co., LLC | $206.03 | 2022-2025 | Orladeyo |
| Amgen INC. | $177.25 | 2021-2023 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $156.24 | 2020-2025 | Eohilia |
| Incyte Corporation | $135.17 | 2021-2023 | Opzelura |
| Alk-Abello, INC | $122.01 | 2019-2023 | Grastek, Ragwitek, Odactra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $97.12 | 2020-2021 | |
| Pharming Healthcare, INC. | $95.98 | 2020-2023 | Ruconest |
| Abbvie INC. | $93.70 | 2022 | |
| Leo Pharma INC. | $85.72 | 2022-2025 | Adbry |
| Ars Pharmaceuticals Operations, INC. | $80.98 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $65.16 | 2023-2024 | Ryaltris |
| Grifols USA, LLC | $62.95 | 2025 | Xembify |
| Shire North American Group INC | $52.01 | 2019 | |
| Blueprint Medicines Corporation | $28.10 | 2023 | Ayvakit |
| Biocryst Pharmaceuticals, INC. | $24.32 | 2020 | |
| Merck Sharp & Dohme LLC | $23.87 | 2023 | |
| Horizon Therapeutics Plc | $22.42 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.